← Back to Search

Radiation

Radiation Therapy for Leukemia

Q: How many individuals have joined the experiment thus far?

<p>Indeed, the details on clinicaltrials.gov demonstrate that this investigation is still recruiting patients. It was initially posted in late June 2021 and has been recently updated at the start of October 2022; 10 people are sought from one location.</p>

Q: Are there any current opportunities to participate in the trial?

<p>Clinicaltrials.gov affirms that recruitment for this study is ongoing, with the initial post dated June 30th 2021 and a recent edit on October 4th 2022.</p>

Phase < 1

Recruiting

Led By Bouthaina S Dabaja

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients diagnosed with new or recurrent myeloid leukemia

Aged >= 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial looks at how well the immune system responds to leukemia tumors after low-dose radiation therapy. They want to see if adding immunotherapy could help future patients receiving radiation for leukemia.

Who is the study for?

This trial is for adults (18+) with new or recurrent myeloid leukemia who can undergo a biopsy and have an ECOG performance status <4. Women must be non-pregnant, not of childbearing potential, or use contraception; men also need to agree to use contraception until the last radiation treatment.Check my eligibility

What is being tested?

The study is looking at how the immune system reacts to leukemia tumors after they've been treated with low dose radiation. It involves procedures like biopsies, collecting biological samples, reviewing electronic health records, and taking photographs of tumors.See study design

What are the potential side effects?

While specific side effects are not listed for these interventions since they're mostly observational and diagnostic in nature, typical risks may include discomfort from biopsies and exposure to radiation during imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with new or recurrent myeloid leukemia.

Select...

I am 18 years old or older.

Select...

My tumor can be biopsied without special imaging.

Select...

I can care for myself and am up and about more than 50% of my waking hours.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in anti-leukemia immune responses

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (biopsy, biospecimen collection)Experimental Treatment4 Interventions

Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biopsy

2014

Completed Phase 4

~850

Biospecimen Collection

2004

Completed Phase 2

~1730

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,967 Previous Clinical Trials

1,804,792 Total Patients Enrolled

Bouthaina S DabajaPrincipal InvestigatorM.D. Anderson Cancer Center

5 Previous Clinical Trials

385 Total Patients Enrolled

Media Library

Low Dose Radiation (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT05035706 — Phase < 1

Myeloid Leukemia Research Study Groups: Treatment (biopsy, biospecimen collection)

Myeloid Leukemia Clinical Trial 2023: Low Dose Radiation Highlights & Side Effects. Trial Name: NCT05035706 — Phase < 1

Low Dose Radiation (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05035706 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have joined the experiment thus far?

"Indeed, the details on clinicaltrials.gov demonstrate that this investigation is still recruiting patients. It was initially posted in late June 2021 and has been recently updated at the start of October 2022; 10 people are sought from one location."

Answered by AI

Are there any current opportunities to participate in the trial?

"Clinicaltrials.gov affirms that recruitment for this study is ongoing, with the initial post dated June 30th 2021 and a recent edit on October 4th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

2021. "Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05035706.